Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 41.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,119 shares of the medical equipment provider’s stock after selling 135,747 shares during the period. Handelsbanken Fonder AB owned about 0.09% of Zimmer Biomet worth $23,503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ZBH. Naples Money Management LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $35,000. Activest Wealth Management raised its position in shares of Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 275 shares during the last quarter. Peoples Bank KS purchased a new stake in shares of Zimmer Biomet in the third quarter valued at about $48,000. Impact Partnership Wealth LLC purchased a new stake in shares of Zimmer Biomet in the third quarter valued at about $52,000. Finally, Blue Trust Inc. grew its holdings in shares of Zimmer Biomet by 48.4% in the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 153 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ZBH shares. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Truist Financial increased their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 23rd. Raymond James raised their price objective on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Barclays raised their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Stock Up 1.1 %

ZBH stock opened at $120.78 on Tuesday. The company’s 50 day moving average is $126.23 and its two-hundred day moving average is $119.37. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $149.25. The stock has a market cap of $24.82 billion, a P/E ratio of 24.70, a PEG ratio of 2.19 and a beta of 1.01. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.88 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.